

EMPLICURE SIGNS DEVELOPMENT AGREEMENT WITH UPPSALA UNIVERSITY REGARDING BIOLOGICAL MEDICINES

As part of broadening Emplicure's project and product development, an agreement has been signed with the Department of Materials Science at Uppsala University, Sweden. The agreement includes advanced materials science characterization of drug formulations developed by Emplicure, as well as collaboration to develop new formulations of biological drugs (biologics).

Medicines have traditionally been manufactured by chemical means, but in recent decades more and more medicines have been manufactured through biological processes. Thanks to this development, there are now new effective treatments for several serious and chronic diseases, such as rheumatism and cancer.

“Using our patented bioceramic platforms with new biological substances and thereby developing innovative biological drugs with specific release profiles will contribute to new and completely unique treatment options for patients. We see great potential in being able to use our bioceramic platforms in biological drugs, with increased patient benefit and more efficient treatment as a result” says CEO Torbjörn W. Larsson, CEO of Emplicure.

For more information, please contact:

Torbjörn W. Larsson

CEO

Phone: +46 (0)70 747 65 99

Email: twl@emplicure.com

Erik Magnusson

CFO, Investor Relations

Phone: +46 (0)708 565 245

Email: erik.magnusson@emplicure.com

Adviser

Certified Adviser is Mangold Fondkommission AB, +46 8 503 015 50, or via ca@mangold.se



Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with tobacco-free nicotine as the first product. Read more at www.emplicure.com